Florida Is Funding Ivermectin Cancer Trials. Dr. William Makis on What's Being Tested | Redacted

Summary

The Redacted host frames chemotherapy as outdated and damaging, and argues that pharmaceutical companies have little incentive to promote inexpensive repurposed drugs. Guest Dr. William Makis supports that view, criticizing chemotherapy’s effects on healthy cells and citing a study he says found only a small long-term survival contribution from chemotherapy. He also criticizes the high prices of newer targeted cancer drugs and an mRNA cancer-vaccine program. These are presented as the speakers’ opinions and claims, not as a balanced review of oncology evidence.

Makis says interest in ivermectin as a possible cancer treatment grew from earlier laboratory and animal research, and that the COVID period brought it more attention. He describes Florida funding clinical research into repurposed drugs, including ivermectin, mebendazole, and fenbendazole. According to him, several human ivermectin trials are underway or planned, many involving metastatic cancers; he says results are not yet available. He also cites a study of mebendazole in metastatic colon cancer and a report involving 200 cancer patients, describing favorable outcomes. The interview does not independently verify these studies or establish that the drugs are effective cancer treatments.

Makis outlines proposed mechanisms: he says ivermectin may affect tumor-growth signals, cancer stem cells, and metastasis, while mebendazole and fenbendazole may interfere with cancer cells’ glucose use and promote cell death. He offers his view that mebendazole may be preferable for brain tumors and some squamous-cell cancers, while fenbendazole may be more promising for certain glandular cancers. He also discusses combining these drugs with conventional cancer treatments. These ideas remain investigational; the interview’s anecdotes and proposed mechanisms do not establish clinical benefit.

Asked about prevention, Makis acknowledges that it has not been studied and calls any possible benefit hypothetical. He describes using blood markers and scans to assess responses, and recounts patient cases he says improved while taking repurposed drugs. He also gives example doses, but no controlled results supporting those protocols are presented. The discussion should not be taken as medical guidance or as a reason to delay or replace evidence-based cancer care.

The interview also discusses Suzy Wiles’s reported breast-cancer treatment, which Makis says included extensive chemotherapy followed by surgery. He says pharmacies sometimes refuse to provide ivermectin and attributes this to lingering suppression from the COVID era and financial incentives. The host and guest further discuss the case of Scott Adams. Makis says Adams tried ivermectin and fenbendazole briefly, later stopped communicating with him, and pursued conventional treatment. Their account and criticism of how the case was handled are presented from their perspective.

Presenters and Contributors

• Redacted host (not identified by name in the subtitles)
• Dr. William Makis, guest